217480 — SD Biotechnologies Co Balance Sheet
0.000.00%
Last trade - 00:00
Consumer DefensivesHighly SpeculativeMicro Cap
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | ARS/A | Annual Audited Accounts |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 15,175 | 22,626 | 16,251 | 15,494 | 27,010 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 21,122 | 17,799 | 16,748 | 6,123 | 2,953 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 77,338 | 86,229 | 80,415 | 44,051 | 59,137 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 51,445 | 52,927 | 59,260 | 48,284 | 15,904 |
Net Goodwill | |||||
Net Intangible Assets | |||||
Long Term Investments | |||||
Long Term Notes Receivable | |||||
Other Long Term Assets | |||||
Total Assets | 137,235 | 146,262 | 146,467 | 96,439 | 76,123 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 33,049 | 53,303 | 84,730 | 77,840 | 30,919 |
Long Term Debt | |||||
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Deferred Income Tax | |||||
Minority Interest | |||||
Total Other Liabilities | |||||
Total Liabilities | 46,532 | 64,311 | 100,510 | 93,343 | 32,117 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
ESOP Debt Guarantee | |||||
Unrealized Gain / Loss | |||||
Other Equity | |||||
Total Equity | 90,704 | 81,951 | 45,957 | 3,096 | 44,005 |
Total Liabilities & Shareholders' Equity | 137,235 | 146,262 | 146,467 | 96,439 | 76,123 |
Total Common Shares Outstanding |